There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 2 | 10 | 2522.6 |
| 3 | 25 | 2522.5 |
| 1 | 9 | 2522.4 |
| 2 | 9 | 2522 |
| 1 | 1 | 2521.9 |
| Ask | Qty | Orders |
|---|---|---|
| 2523.9 | 6 | 13 |
| 2524 | 3 | 4 |
| 2524.1 | 3 | 6 |
| 2524.2 | 3 | 47 |
| 2524.3 | 6 | 88 |
Annual Revenue,rose 14.85%, in the last year to ₹14,636.43 Cr. Its sector's average revenue growth for the last fiscal year was 12.14%.Quarterly Revenue,rose 11.81% YoY to ₹3,557.22 Cr. Its sector's average revenue growth YoY for the quarter was 12.58%.Quarterly Net profit,rose 31.75% YoY to ₹554.35 Cr. Its sector's average net profit growth YoY for the quarter was 13.28%.Mankind Pharma Limited is one of India’s leading pharmaceutical companies, founded in 1991 and commencing operations in 1995. The Company develops, manufactures and markets a broad range of pharmaceutical formulations across acute and chronic therapies, along with consumer healthcare products including condoms, pregnancy detection kits, antacid powders, vitamin and mineral supplements, oral contraceptives and medicated anti-acne preparations.
The Company has established a strong domestic presence and expanded globally with subsidiaries in the US, Singapore, the UAE, Germany, Malaysia and the Philippines. A major milestone was the acquisition of Bharat Serums and Vaccines (BSV) in October 2024, strengthening its position in super-specialty therapies and women’s health. As on March 31, 2025, Mankind Pharma had 38 subsidiaries as per the consolidated financial statements.
Mankind operates 32 manufacturing facilities and 6 R&D centres, with more than 75% in-house manufacturing and over 95% local procurement of raw materials. The Company has an installed capacity of 44+ billion units and employs 5,100+ manufacturing staff and 730 scientists, including 73 PhDs. Its distribution is supported by 16,000+ stockists, a 17,700+ strong field force, and coverage of over 5 lakh doctors.
For Q4 FY26, Mankind Pharma Limited reported: Revenue (Net Sales): ₹25818.20 Cr - Down -1.93% year-on-year from ₹26326.80 Cr in Q3 FY26. Net Income (PAT): ₹7136.10 Cr - Up 58.77% year-on-year from ₹4494.70 Cr in Q3 FY26.
The intraday low for Mankind Pharma Limited on the NSE today was ₹2,508.00. The stock's 52-week low stands at ₹1,909.70, recorded on 23 Mar 2026. Today's low is 31.33% above the 52-week low, indicating the stock is trading well above its yearly lows.
The intraday high for Mankind Pharma Limited on the NSE today (07 Jul 2026) was ₹2,564.50. This compares to the 52-week high of ₹2,716.50 recorded on 15 Jul 2025. Today's high was -5.60% below the 52-week high.
As of 07 Jul 2026, the share price of Mankind Pharma Limited is ₹2,521.30 on the NSE and ₹2,522.05 on the BSE. The stock opened at ₹2,559.90, touched a high of ₹2,564.50 and a low of ₹2,508.00 during today's session.
Over the last 6 months, Mankind Pharma Limited has given a return of 9.94%. The stock was priced at ₹2,311.80 on 07 Jan 2026 and has Rise to ₹2,521.30 as of 07 Jul 2026, a change of ₹209.50 per share.
Mankind Pharma Limited has delivered a return of 24.58% over the last 3 months. The stock was trading at ₹2,040.10 on 07 Apr 2026 and is currently at ₹2,521.30 as of 07 Jul 2026, reflecting a Gain of ₹481.20 per share over this period.
No,Mankind Pharma Limited has not declared any dividend over the past 5 years. The company paid a total dividend of 1.00 per share between FY2022 and FY2026, with the most recent dividend of ₹1.00 per share for Jul 25, with an ex-dividend date of 08 Aug 2025. At the current market price of ₹2,521.30, the trailing dividend yield of Mankind Pharma Limited stands at 1.00%.
Mankind Pharma Limited has delivered a N/A% absolute return over the past 5 years, equivalent to a CAGR of N/A% per annum. The stock was priced at ₹N/A in Jul 2021 and has fallen to ₹2,521.30 as of 07 Jul 2026. An investment of ₹1,00,000 in Mankind Pharma Limited five years ago would be worth ₹N/A today.
The all-time high (ATH) for Mankind Pharma Limited was ₹2,998.40, recorded on 23 Dec 2024. At the current price of ₹2,521.30, the stock is trading 15.91% below its all-time high. The all-time low recorded was ₹1,322.65 on 24 May 2023.
Mankind Pharma Limited has delivered 5.44% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹2,716.50 on 15 Jul 2025 and a 52-week low of ₹1,909.70 on 23 Mar 2026. It is currently trading at ₹2,521.30 as of 07 Jul 2026.
